also known erα coregulatorbinding novel antiestrogen experimental hormonal antineoplastic agent researched potential treatment estrogen receptorpositive breast competitive antagonist estrogen receptor er like conventional antiestrogens tamoxifen fulvestrant instead binding ligandbinding site er interacts different part erα blocks interactions erα coregulators necessary receptor act regulate gene designed bind coregulator binding region erα inhibit erαcoactivator interaction although precise binding site mode action yet fully elucidated nonetheless clear binds within domain orally active smallmolecule tribenzamide compound shows good antiestrogenic potency vitro minimal indications toxicity vivo animals even doses much higher therapeutic compound mimics nuclear receptor binding motif appears critical interaction erα able disrupt interactions erα erαbinding coregulators including steroid receptor coactivator steroid receptor coactivator proline glutamic acid leucinerich protein blocked estradiolinduced proliferation erpositive breast cancer cell lines halfmaximal inhibitory concentration values ranging nm nm effective tamoxifen fulvestrant inhibiting growth breast cancer cell inactive ernegative breast cancer cell contrast conventional antiestrogens like tamoxifen fulvestrant found block liganddependent ligandindependent er signaling well er signaling therapysensitive therapyresistant breast cancer addition disrupted interactions erα many erαbinding coregulators affected conventional antiestrogens like tamoxifen proteins also induced apoptosis breast cancer cells unlike efforts underway assess human clinical